Literature DB >> 35460240

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.

Lisa G Rider1, Christine G Parks2, Jesse Wilkerson3, Adam I Schiffenbauer1, Richard K Kwok4, Payam Noroozi Farhadi1, Sarvar Nazir1, Rebecca Ritter3, Emily Sirotich5, Kevin Kennedy6, Maggie J Larche5, Mitchell Levine6, Sebastian E Sattui7, Jean W Liew8, Carly O Harrison9, Tarin T Moni10, Aubrey K Miller4, Michael Putman11, Jonathan Hausmann12, Julia F Simard13, Jeffrey A Sparks14, Frederick W Miller1.   

Abstract

OBJECTIVE: To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD).
METHODS: An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression.
RESULTS: Flares requiring a change in treatment following COVID-19 vaccination were reported by 4.9% of patients. Compared with rheumatoid arthritis, certain SRD, including systemic lupus erythematosus (OR 1.51, 95% CI 1.03, 2.20), psoriatic arthritis (OR 1.95, 95% CI 1.20, 3.18) and polymyalgia rheumatica (OR 1.94, 95% CI 1.08, 2.48) were associated with higher odds of flare, while idiopathic inflammatory myopathies were associated with lower odds for flare (OR 0.54, 95% CI 0.31-0.96). The Oxford-AstraZeneca vaccine was associated with higher odds of flare relative to the Pfizer-BioNTech vaccine (OR 1.44, 95% CI 1.07, 1.95), as were a prior reaction to a non-COVID-19 vaccine (OR 2.50, 95% CI 1.76, 3.54) and female sex (OR 2.71, 95% CI 1.55, 4.72).
CONCLUSION: SRD flares requiring changes in treatment following COVID-19 vaccination were uncommon in this large international study. Several potential risk factors, as well as differences by disease type, warrant further examination in prospective cohorts. Published by Oxford University Press on behalf of the British Society for Rheumatology 2022. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  COVID-19; disease flare; systemic rheumatic diseases; vaccine

Mesh:

Substances:

Year:  2022        PMID: 35460240      PMCID: PMC9248066          DOI: 10.1093/rheumatology/keac249

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.046


  18 in total

1.  Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City.

Authors:  Medha Barbhaiya; Jonah M Levine; Vivian P Bykerk; Deanna Jannat-Khah; Lisa A Mandl
Journal:  Ann Rheum Dis       Date:  2021-06-22       Impact factor: 19.103

2.  Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.

Authors:  Vivian P Bykerk; Nancy Shadick; Michelle Frits; Clifton O Bingham; Iain Jeffery; Christine Iannaccone; Michael Weinblatt; Daniel H Solomon
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

3.  Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.

Authors:  Jin Kyun Park; Min Ah Lee; Eun Young Lee; Yeong Wook Song; Yunhee Choi; Kevin L Winthrop; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2017-05-03       Impact factor: 19.103

4.  Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink.

Authors:  Georgina Nakafero; Matthew J Grainge; Puja R Myles; Christian D Mallen; Weiya Zhang; Michael Doherty; Jonathan S Nguyen-Van-Tam; Abhishek Abhishek
Journal:  Ann Rheum Dis       Date:  2019-04-29       Impact factor: 19.103

5.  Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Authors:  Sebastian Eduardo Sattui; Jean W Liew; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco Ugarte-Gil; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider
Journal:  RMD Open       Date:  2021-09

6.  Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines.

Authors:  Yong Fan; Yan Geng; Yu Wang; Xuerong Deng; Guangtao Li; Juan Zhao; Lanlan Ji; Xiaohui Zhang; Zhibo Song; Haoze Zhang; Xiaoying Sun; Dai Gao; Wenhui Xie; Hong Huang; YanJie Hao; Zhuoli Zhang
Journal:  Ann Rheum Dis       Date:  2021-11-25       Impact factor: 19.103

7.  COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Authors:  Michael Putman; Kevin Kennedy; Emily Sirotich; Jean W Liew; Sebastian E Sattui; Tarin T Moni; Akpabio A Akpabio; Deshire Alpizar-Rodriguez; Saskya Angevare; Richard P Beesley; Francis Berenbaum; Inita Bulina; Yu Pei Eugenia Chock; Richard Conway; Ali Duarte-García; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred H J Kim; David F L Liew; Chieh Lo; Elsa F Mateus; Bruce Miller; Serena Mingolla; Michal Nudel; Jasvinder A Singh; Namrata Singh; Manuel F Ugarte-Gil; John Wallace; Kristen J Young; Erick Adrian Zamora-Tehozol; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie J Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Jonathan S Hausmann; Jeffrey A Sparks; Julia F Simard
Journal:  Lancet Rheumatol       Date:  2022-02-08

8.  Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.

Authors:  Renaud Felten; Marc Scherlinger; Jacques-Eric Gottenberg; Jean Sibilia; Thierry Martin; Laurent Arnaud; Aurélien Guffroy; Vincent Poindron; Alain Meyer; Margherita Giannini; Anne-Sophie Korganow; Christelle Sordet; Emmanuel Chatelus; Rose-Marie Javier; Aurore Meyer; Luc Pijnenburg; Jean-François Kleinmann
Journal:  Arthritis Res Ther       Date:  2021-07-13       Impact factor: 5.156

9.  Adverse events after first COVID-19 vaccination in patients with autoimmune diseases.

Authors:  Laura Boekel; Laura Y Kummer; Koos P J van Dam; Femke Hooijberg; Zoé van Kempen; Erik H Vogelzang; Luuk Wieske; Filip Eftimov; Ronald van Vollenhoven; Taco W Kuijpers; S Marieke van Ham; Sander W Tas; Joep Killestein; Maarten Boers; Mike T Nurmohamed; Theo Rispens; Gertjan Wolbink
Journal:  Lancet Rheumatol       Date:  2021-06-18

10.  Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients.

Authors:  Emma Stevens; Michael E Weinblatt; Elena Massarotti; Frances Griffin; Srinivas Emani; Sonali Desai
Journal:  ACR Open Rheumatol       Date:  2020-05-15
View more
  1 in total

Review 1.  The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.

Authors:  Yan Xie; Yang Liu; Yi Liu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.